EP547 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	1
94	Primary sclerosing cholangitis	1

93. Primary biliary cholangitis

---

Clinical trials : 298 /  Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05525520 (ClinicalTrials.gov)	October 6, 2022	30/8/2022	Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Pruritus	Drug: EP547;Drug: Placebo	Escient Pharmaceuticals, Inc	NULL	Recruiting	18 Years	80 Years	All	58	Phase 2	United States

94. Primary sclerosing cholangitis

---

Clinical trials : 148 /  Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05525520 (ClinicalTrials.gov)	October 6, 2022	30/8/2022	Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis	Pruritus	Drug: EP547;Drug: Placebo	Escient Pharmaceuticals, Inc	NULL	Recruiting	18 Years	80 Years	All	58	Phase 2	United States